2025 General Assembly and Seminar: Health Technology Assessment (HTA) – Unknown makes unloved? The essentials for Nuclear Medicine

Published on: December 5, 2024

  • Date: February 15, 2025
  • RIZIV/INAMI accreditation:
    • 2 CP in Ethics & Economy will be requested1
    • FANC/AFCN continuing education accreditation will be requested
  • Venue: ULB, Campus Erasme – Auditoire Elisabeth Wollast (building W, E.W.1.307), 808 route de Lennik, 1070 Anderlecht
The registration is now open! Click here to register now! Registration will close on February 09, 2025.
1 RIZIV/INAMI accreditation for nuclear medicine physicians is available for BELNUC members only.

Health Technology Assessment (HTA)

A health technology assessment (HTA) is an evidence-based scientific process that enables national authorities to assess the relative effectiveness of new or existing health technologies, including nuclear medicine applications such as PET/CT, (new) radiopharmaceuticals, radioligand therapies… It focuses in particular on the added value of a health technology compared to other new or existing technologies and plays a crucial role in shaping the future of healthcare systems across the globe.
In Belgium, the landscape of HTA is shaped by both national needs and its integration into broader European health policies. With Belgium’s highly developed healthcare system, HTA is a vital tool in ensuring the sustainability of healthcare spending while maintaining quality patient outcomes. The country’s involvement in European HTA networks, like EUnetHTA, fosters collaboration in evaluating cross-border health technologies, ensuring that Belgium remains at the forefront of scientific and clinical advancements.

Programme

Moderators: Dr Anne-Leen Deleu (H.U.B.) – Prof Dr Nadia Withofs (CHU de Liège)
09:00-09:45
 Andrew Scott, MD, PhD (Austin Health, Melbourne, Australia): HTA within the nuclear medicine field – the extra-EU/Australian perspective
09:45-10:30
 Sietse van Mossel, MSc, PhD candidate HTA (Leiden University, The Netherlands) and/or Dennis Vriens, MD, PhD (Radboudumc, Nijmegen, The Netherlands): HTA within the nuclear medicine field – the European/Dutch perspective
10:30-11:00
 Break
11:00-11:30
 Mattias Neyt, MSc, PhD (KCE – Belgian Health Care Knowledge Centre, Belgium): HTA within Belgium –Belgian HTA guidelines and the impact of the new EU Regulation 2021/2282 on health technology assessment (HTAR) applying from January 12, 2025
11:30-12:30      
 General Assembly

Campus Erasme Map

Building W is located on Rue Meylemeersch, within walking distance of the centre of the campus on Route de Lennik. Plan Erasme